<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03789136</url>
  </required_header>
  <id_info>
    <org_study_id>NL58188.081.16</org_study_id>
    <nct_id>NCT03789136</nct_id>
  </id_info>
  <brief_title>The Effect of Colon Cancer on Muscle Gene Expression, Body Composition, Muscle Function, and Muscle Metabolism</brief_title>
  <acronym>COMUNEX</acronym>
  <official_title>The Effect of Colon Cancer on Muscle Gene Expression, Body Composition, Muscle Function, and Muscle Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gelderse Vallei Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Cancer cachexia is a complex metabolic syndrome characterized by clinically&#xD;
      relevant loss of muscle mass with or without loss of fat mass. To determine how treatment&#xD;
      methods can be most effective, full insight in changes in gene expression, body composition,&#xD;
      muscle function and muscle metabolism are of great importance.&#xD;
&#xD;
      Objective: Main aim of the study is to investigate the differences in gene expression, body&#xD;
      composition, muscle function and muscle metabolism in colon cancer patients compared to&#xD;
      controls.&#xD;
&#xD;
      Study design: Observational study Study population: 40 colon cancer patients undergoing a&#xD;
      tumor resection (30 primary tumor and 10 liver metastases) and 15 control patients undergoing&#xD;
      an inguinal hernia repair (♂, 10) or an abdominal hysterectomy (♀, 5).&#xD;
&#xD;
      Main study parameters/endpoints: Primary study parameter will be gene expression&#xD;
      (transcriptomic and polymerase chain reaction analyses of muscle biopsies). Secondary&#xD;
      parameters will be body composition (determined in available CT scans and bio impedance&#xD;
      analysis and with DEXA), muscle function parameters (grip and knee flexion/extension strength&#xD;
      and measured in a biopsy), metabolic markers (measured in fat and muscle biopsies),&#xD;
      biochemical markers (measured in blood/serum) and gene expression of fat biopsies.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The investigators expect no additional risk for the subjects due to the proposed&#xD;
      measurements. Biopsies will be taken during the planned operation and therefore is not&#xD;
      expected to cause a significant increase in burden for the patient. All other measurements&#xD;
      are non-invasive, observational measurements with no risk of any harmful side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle gene expression</measure>
    <time_frame>Biopsy during surgery</time_frame>
    <description>Muscle gene expression measured by microarray in a muscle biopsy taken from the rectus abdominis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Before surgery</time_frame>
    <description>Measured using single slice staining of CT scan made for diagnostic purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function</measure>
    <time_frame>Before surgery</time_frame>
    <description>Measured using hand-grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle protein metabolism</measure>
    <time_frame>Biopsy during surgery</time_frame>
    <description>Measured in a muscle biopsy taken from the rectus abdominis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue gene expression</measure>
    <time_frame>Biopsy during surgery</time_frame>
    <description>Adipose tissue gene expression measured using PCR or micro-array in abdominal and subcutaneous fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine parameters in the blood</measure>
    <time_frame>Blood taken prior to surgery</time_frame>
    <description>Blood plasma cytokine levels measured using multiplex or similar technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micro-nutrient parameters in the blood</measure>
    <time_frame>Blood taken prior to surgery</time_frame>
    <description>Micro-nutrient levels in the blood measured using LCMS, ELISA or similar techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol levels in the blood</measure>
    <time_frame>Blood taken prior to surgery</time_frame>
    <description>Cholesterol levels in the blood measured by GCMS</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Cachexia; Cancer</condition>
  <arm_group>
    <arm_group_label>Primary colon cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver metastases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Inguinal hernia (control)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal hysterectomy (control)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable, observational study</intervention_name>
    <description>Not applicable, observational study</description>
    <arm_group_label>Abdominal hysterectomy (control)</arm_group_label>
    <arm_group_label>Inguinal hernia (control)</arm_group_label>
    <arm_group_label>Liver metastases</arm_group_label>
    <arm_group_label>Primary colon cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        40 colon cancer (CC) patients (♀ and ♂) undergoing primary tumor resection operation (30&#xD;
        patients) or liver metastases surgery (10 patients) and 15 control patients undergoing an&#xD;
        inguinal hernia repair (♂, 10) or an abdominal hysterectomy (♀, 5) will be included in the&#xD;
        study. Since the investigators do not know the number of patients in the colon cancer group&#xD;
        willing to cooperate in the study, the investigators decided to take 5 patients of each&#xD;
        control group (50% men and women). Note: during the study the investigators see more men&#xD;
        than women joining the study so therefore the investigators raised the number of male&#xD;
        controls to 10.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CC patients:&#xD;
&#xD;
        In order to be eligible to participate in this study, a subject must meet all of the&#xD;
        following inclusion criteria:&#xD;
&#xD;
          -  Diagnosed with primary colon cancer (30) or liver metastases due to colon cancer(10)&#xD;
&#xD;
          -  Eligible for a primary tumor or liver metastases resection procedure&#xD;
&#xD;
               -  Controls:&#xD;
&#xD;
          -  Eligible for an inguinal hernia repair (♂, 10) or an abdominal hysterectomy (♀, 5)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CC patients:&#xD;
&#xD;
        A potential subject who meets any of the following criteria will be excluded from&#xD;
        participation in this study:&#xD;
&#xD;
          -  Having had chemotherapy or an operational procedure of the abdomen in the past 6&#xD;
             months&#xD;
&#xD;
          -  Suffering from malabsorption&#xD;
&#xD;
               -  Controls:&#xD;
&#xD;
          -  Having had treatment for previous or current tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>For the control group the investigators include men with inguinal hernia and women eligible for abdominal hysterectomy.</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaske van Norren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaske van Norren, PhD</last_name>
    <phone>+31317485790</phone>
    <email>klaske.vannorrren@wur.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gelderse Vallei Hospital</name>
      <address>
        <city>Ede</city>
        <state>Gelderland</state>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dik Snijdelaar, md</last_name>
      <email>snijdelaarD@zgv.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2018</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

